Cowen analyst Tyler Van Buren raised the firm’s price target on Moderna to $150 from $130 and keeps a Market Perform rating on the shares. The analyst adjusted Q4 COVID-19 vaccine sales and OpEx was revised up slightly while adding $1.5B of peak PCV profits.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRNA:
- Pharma Industry Could Benefit from Rise in Medicine Spending
- Moderna Gets Further Validation for Its mRNA Platform, Says Analyst
- Early notable gainers among liquid option names on January 18th
- Moderna price target raised to $208 from $191 at Chardan
- Unusually active option classes on open January 18th